Another study investigated the effect of time from breast cancer diagnosis to adjuvant trastuzumab in HER2-positive patients, demonstrating superior survival outcomes when trastuzumab is initiated within 6 months of diagnosis [13]. This evidence concerns the gene ERBB2 and breast cancer.